The ADRC provides specialized resources to accelerate research on the role of metabolic and vascular factors in the causes of Alzheimer’s disease and for the development of novel interventions.
Highlights include:
- Clinical, cognitive biomarker and neuroimaging data as well as DNA, blood and cerebrospinal fluid from approximately 1,500 well-characterized participants from the ADRC and affiliated studies. More participants will be added over the next five years, with an emphasis on subjects from populations that are under-represented in research.
- Database of longitudinal clinical trial participants with and without metabolic disorders and cardiovascular disease, who range from normal cognition and mild cognitive impairment, to Alzheimer’s disease or mixed dementia, and who may be available for other clinical trials.
- A human brain bank that is under development at Wake Forest University School of Medicine. In addition, our affiliated brain bank at the University of Washington offers prioritized access to Wake Forest investigators, with over 600 well-characterized cases.
- A repository of non-human primate (rhesus, vervets and cynomolgus) biospecimens, data and neuroimaging from multiple studies, many of which parallel human metabolic disorders, aging and Alzheimer’s disease neuropathology.
- Access to Alzheimer’s disease repositories and data through the National Alzheimer’s Coordinating Center (NACC), National Cell Repository for AD (NCRAD), AD Genetics Consortium (ADGC), and National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS).
- Education and training for community health care professionals and the public about early detection, prevention and treatment of Alzheimer’s.
- Annual development project awards up to $50,000 each and pilot grant awards up to $20,000 each.
